Taiwan
· Delayed Price · Currency is TWD Bioray Biotech Statistics
Total Valuation
Bioray Biotech has a market cap or net worth of TWD 635.45 million. The enterprise value is 585.66 million.
| Market Cap | 635.45M |
| Enterprise Value | 585.66M |
Important Dates
The next estimated earnings date is Friday, April 18, 2025.
| Earnings Date | Apr 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioray Biotech has 29.83 million shares outstanding. The number of shares has increased by 1.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 29.83M |
| Shares Change (YoY) | +1.54% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 17.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.49 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | 165.31 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -37.07 |
| EV / Sales | 3.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 152.36 |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.36 |
| Quick Ratio | 2.52 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | 23.61 |
| Interest Coverage | -18.73 |
Financial Efficiency
Return on equity (ROE) is -3.69% and return on invested capital (ROIC) is -3.10%.
| Return on Equity (ROE) | -3.69% |
| Return on Assets (ROA) | -2.86% |
| Return on Capital (ROIC) | -3.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.47% |
| 50-Day Moving Average | 20.97 |
| 200-Day Moving Average | 24.52 |
| Relative Strength Index (RSI) | 56.63 |
| Average Volume (20 Days) | 4,641 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bioray Biotech had revenue of TWD 183.57 million and -15.80 million in losses. Loss per share was -0.53.
| Revenue | 183.57M |
| Gross Profit | 67.59M |
| Operating Income | -25.52M |
| Pretax Income | -19.43M |
| Net Income | -15.80M |
| EBITDA | -7.39M |
| EBIT | -25.52M |
| Loss Per Share | -0.53 |
Balance Sheet
The company has 140.55 million in cash and 90.76 million in debt, giving a net cash position of 49.79 million or 1.67 per share.
| Cash & Cash Equivalents | 140.55M |
| Total Debt | 90.76M |
| Net Cash | 49.79M |
| Net Cash Per Share | 1.67 |
| Equity (Book Value) | 416.97M |
| Book Value Per Share | 13.98 |
| Working Capital | 205.42M |
Cash Flow
In the last 12 months, operating cash flow was 6.42 million and capital expenditures -2.58 million, giving a free cash flow of 3.84 million.
| Operating Cash Flow | 6.42M |
| Capital Expenditures | -2.58M |
| Free Cash Flow | 3.84M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 36.82%, with operating and profit margins of -13.90% and -8.61%.
| Gross Margin | 36.82% |
| Operating Margin | -13.90% |
| Pretax Margin | -10.58% |
| Profit Margin | -8.61% |
| EBITDA Margin | -4.03% |
| EBIT Margin | -13.90% |
| FCF Margin | 2.09% |
Dividends & Yields
Bioray Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.54% |
| Shareholder Yield | -1.54% |
| Earnings Yield | -2.47% |
| FCF Yield | 0.60% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioray Biotech has an Altman Z-Score of 4.49.
| Altman Z-Score | 4.49 |
| Piotroski F-Score | n/a |